MCD vs PFE: Which Is the Better Buy?
Side-by-side comparison of McDonald's Corporation and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-20.
McDonald's Corporation · Consumer Cyclical
$267.71
+20.6% upside to fair value
Med Conviction
Grade C+
High Quality
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
MCD has more upside to fair value
(+20.6%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MCD |
PFE |
| Current Price |
$267.71 |
$25.22 |
| Fair Value Estimate |
$322.85 |
$25.92 |
| Upside to Fair Value |
+20.6%
|
+2.8%
|
| Market Cap |
$190.2B |
$143.7B |
| Forward P/E |
—
|
19.2x
|
| EV / EBITDA |
16.4x
|
12.3x
|
| Price / Sales |
6.9x
|
2.3x
|
| Price / FCF |
27.0x
|
15.2x
|
| Revenue Growth YoY |
+9.4%
|
+5.4%
|
| Gross Margin |
57.4%
|
69.3%
|
| Operating Margin |
46.0%
|
23.4%
|
| Return on Equity |
-433.9%
|
8.4%
|
| Dividend Yield |
2.75% |
0% |
| FCF Yield |
3.7%
|
6.6%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
McDonald's is a global quick-service restaurant franchisor and real-estate platform whose approximately 95% franchised restaurant base generates unusually high-margin, recurring royalty and rent income, supporting a 46.0% operating margin and 31.6% net margin. Business quality is high because its brand, global purchasing scale, nearly 29,000 drive-thrus, digital ecosystem and 210 million 90-day a…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
MCD |
PFE |
| Zone Low |
$242.14 |
$19.44 |
| Zone High |
$274.42 |
$22.03 |
| In Buy Zone? |
Yes
|
No
|